Etiology
May involve the arrest of maturation of the osteoblasts caused by USP6 overexpression and dysregulation of autocrine BMP (bone morphology protein) signaling (Lau et al., 2010) .
Epidemiology
Usually seen in patients aged 10-20 years; represents about 5% of primary bone tumours; slightly more frequent in female patients.
Clinics
Forms a spongy hemorrhagic mass; symptoms are pain, swelling, pathological fractures. About eleven cases to date have been described with a t(16;17)(q22;p13), 7 female patients aged 5, 7, 13, 13, 14, 15, and 17 years, and 4 male patients aged 10, 12, 13, and 30 years (Panoutsakopoulos et al., 1999; Herens et al., 2001; Wyatt-Ashmead et al., 2001; Althof et al., 2004; Oliveira et al., 2004) .
Treatment
Surgical curetage.
Prognosis
Recurrence occurs in one fourth of cases.
Cytogenetics

Cytogenetics Morphological
In 8 of the 11 cases, the t(16;17)(q22;p13) was the sole anomaly.
Genes involved and proteins
CDH11
Location 16q22 Protein Cell-cell adhesion molecule that mediates adhesion by Ca2+-dependent interactions. Its intracellular domain is anchored to the actin cytoskeleton through alpha and beta-catenin. Role in maintaining tissue architecture and cell polarity, limiting cell movement and proliferation. CDH11 antagonizes Wnt/beta-catenin signaling pathway, induces apoptosis, and regulates epithelialmesenchymal transition (Li et al., 2011) . CDH11 is involved in various cancers. Tumor suppressor function.
USP6
Location 17p13 Protein USP6, also called TRE17/ubiquitin-specific protease 6 (USP6), is a deubiquitinase. It is the first deubiquitinating enzyme to activate NF-KB, and requires both catalytic subunits of IKK (IKKalpha and IKKbeta) (Pringle et al., 2011) .
